Investigation of cortisol levels in patients with anxiety disorders: A structured review

Current Topics in Behavioral Neurosciences

Volumn 18, Issue , 2014, Pages 191-216

  Elnazer, Hesham Yousry ^a,b   Baldwin, David S ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b University Department of Psychiatry   (United Kingdom)

Author keywords

Anxiety disorder; Cortisol; Panic; Phobia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; ALPRAZOLAM; ATRIAL NATRIURETIC FACTOR; CLONIDINE; DIAZEPAM; FLUMAZENIL; HYDROCORTISONE; NORADRENALIN; PAROXETINE; TETRAGASTRIN;

AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERVENTILATION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PANIC; PHOBIA; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL PHOBIA; SYSTEMATIC REVIEW; UPREGULATION;

EID: 84921761034     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2014_299     Document Type: Article

References (154)

1. Abelson JL, Curtis GC (1989) Cardiac and neuroendocrine responses to exposure therapy in height phobics: desynchrony within the physiological response system. Behav Res Ther 27:561–567.
2. Abelson JL, Nesse RM, Vinik A (1991) Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 29:1220–1223.
3. Abelson JL, Nesse RM, Vinik AI (1994) Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry 36:84–96.
4. Abelson JL, Curtis GC (1996a) Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 53:323–331.
5. Abelson JL, Curtis GC (1996b) Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry 153:69–73.
6. Abelson JL, Curtis GC, Cameron OG (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res 30:79–93.
7. Abelson JL, Liberzon I, Young EA et al (2005) Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Arch Gen Psychiatry 62:668–675.
8. Ahs F, Furmark T, Michelgård A et al (2006) Hypothalamic blood flow correlates positively with stress-induced cortisol levels in subjects with social anxiety disorder. Psychosom Med 68:859–862.
9. Alfano CA, Reynolds K, Scott N et al (2013) Polysomnographic sleep patterns of non-depressed, non-medicated children with generalized anxiety disorder. J Affect Disord 147(1–3):379–384.
10. Alpers GW, Abelson JL, Wilhelm FH et al (2003) Salivary cortisol response during exposure treatment in driving phobics. Psychosom Med 65:679–687.
11. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Publishing, Washington
12. Avery DH, Osgood TB, Ishiki DM et al (1985) The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am J Psychiatry 142:844–848.
13. Baldwin DS, Allgulander C, Altamura AC et al (2010) Manifesto for a european anxiety disorders research network. Eur Neuropsychopharmacol 20:426–432.
14. Baldwin DS, Pallanti S, Zwanzger P (2013) Developing a european research network to address unmet needs in anxiety disorders. Neurosci Biobehav Rev 37:2312–2317.
15. Bandelow B, Sengos G, Wedekind D et al (1997) Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. Pharmacopsychiatry 30:113–117. Erratum in: Pharmacopsychiatry 1997 30, 278.
16. Bandelow B, Wedekind D, Pauls J et al (2000a) Salivary cortisol in panic attacks. Am J Psychiatry 157:454–456.
17. Bandelow B, Wedekind D, Sandvoss V et al (2000b) Diurnal variation of cortisol in panic disorder. Psychiatry Res 95:245–250.
18. Belgorodsky A, Knyazhansky L, Loewenthal U et al (2005) Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder. Depress Anxiety 21:143–148. Erratum in: Depress Anxiety 2005 21:203.
19. Brambilla F, Bellodi L, Perna G et al (1992) Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiol 26:12–22.
20. Brambilla F, Bellodi L, Arancio C et al (1995) Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinol 20:11–19.
21. Brand S, Annen H, Holsboer-Trachsler E et al (2011) Intensive 2-day cognitive-behavioral intervention decreases cortisol secretion in soldiers suffering from specific phobia to wear protective mask. J Psychiatr Res 45:1337–1345.
22. Bridges M, Yeragani VK, Rainey JM et al (1986) Dexamethasone suppression test in patients with panic attacks. Biol Psychiatry 21(8–9):853–855.
23. Broocks A, Bandelow B, George A et al (2000) Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15:153–161.
24. Broocks A, Bandelow B, Koch K et al (2002) Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder. Neuropsychopharmacol 27:270–278.
25. Broocks A, Meyer T, Opitz M et al (2003) 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 13:153–164.
26. Carson SW, Halbreich U, Yeh CM et al (1988) Altered plasma dexamethasone and cortisol suppressibility in patients with panic disorders. Biol Psychiatry 24:56–62.
27. Charney DS, Heninger GR, Jatlow PI (1985) Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42:233–243.
28. Charney DS, Woods SW, Goodman WK et al (1987a) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144:1030–1036.
29. Charney DS, Woods SW, Goodman WK et al (1987b) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacol 92:14–24.
30. Chaudieu I, Beluche I, Norton J et al (2008) Abnormal reactions to environmental stress in elderly persons with anxiety disorders: evidence from a population study of diurnal cortisol changes. J Affect Disord 106:307–313.
31. Cohn JB, Wilcox CS, Meltzer HY (1986) Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. Am J Med 80(3B):36–40.
32. Coplan JD, Papp LA, Pine D et al (1997) Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 54:643–648.
33. Coplan JD, Goetz R, Klein DF et al (1998) Plasma cortisol concentrations preceding lactateinduced panic. Psychological, biochemical, and physiological correlates. Arch Gen Psychiatry 55:130–136.
34. Coryell W, Noyes R Jr, Clancy J et al (1985) Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks. Psychiatry Res 15:301–311.
35. Coryell W, Noyes R (1988) HPA axis disturbance and treatment outcome in panic disorder. Biol Psychiatry 24:762–766.
36. Coryell W, Noyes R Jr, Schlechte J (1989) The significance of HPA axis disturbance in panic disorder. Biol Psychiatry 25:989–1002.
37. Coryell W, Noyes R Jr, Reich J (1991) The prognostic significance of HPA-axis disturbance in panic disorder: a 3-year follow-up. Biol Psychiatry 29:96–102.
38. Cottraux J, Claustrat B (1984) The dexamethasone suppression test in agoraphobia with panic attacks. 30 cases. Encephale 10:267–272 (French)
39. Curtis GC, Abelson JL, Gold PW (1997) Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 41:76–85.
40. Den Boer JA, Westenberg HG (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 102:85–94
41. de Quervain DJ, Margraf J (2008) Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: a novel therapeutic approach. Eur J Pharmacol 583:365–371
42. de Quervain DJ, Bentz D, Michael T et al (2011) Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 108:6621–6625.
43. DeVane CL, Ware MR, Emmanuel NP et al (1999) Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 14:345–351.
44. Dorn LD, Burgess ES, Friedman TC et al (1997) The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82:912–919.
45. Erhardt A, Ising M, Unschuld PG et al (2006) Regulation of the hypothalamic-pituitaryadrenocortical system in patients with panic disorder. Neuropsychopharmacol 31:2515–2522.
46. Essex MJ, Klein MH, Slattery MJ et al (2010) Early risk factors and developmental pathways to chronic high inhibition and social anxiety disorder in adolescence. Am J Psychiatry 167:40–46.
47. Faludi G, Kaskó M, Perényi A et al (1986) The dexamethasone suppression test in panic disorder and major depressive episodes. Biol Psychiatry 21:1008–1014.
48. Fava M, Rosenbaum JF, MacLaughlin RA et al (1989) Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res 28:345–350.
49. Fredrikson M, Sundin O, Frankenhaeuser M (1985) Cortisol excretion during the defense reaction in humans. Psychosom Med 47:313–319.
50. Furlan PM, DeMartinis N, Schweizer E et al (2001) Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress. Biol Psychiatry 50:254–259.
51. Garcia-Leal C, Parente AC, Del-Ben CM et al (2005) Anxiety and salivary cortisol in symptomatic and nonsymptomatic panic patients and healthy volunteers performing simulated public speaking. Psychiatry Res 133:239–252.
52. Germine M, Goddard AW, Sholomskas DE et al (1994) Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54:115–133.
53. Gerra G, Zaimovic A, Zambelli U et al (2000) Neuroendocrine responses to psychological stress in adolescents with anxiety disorder. Neuropsychobiol 42:82–92.
54. Goldstein S, Halbreich U, Asnis G et al (1987) The hypothalamic-pituitary-adrenal system in panic disorder. Am J Psychiatry 144:1320–1323.
55. Grunhaus L, Tiongco D, Haskett RF et al (1987) The dexamethasone suppression test in inpatients with panic disorder or agoraphobia with panic attacks. Biol Psychiatry 22:517–521.
56. Hek K, Direk N, Newson RS et al (2013) Anxiety disorders and salivary cortisol levels in older adults: a population-based study. Psychoneuroendocrinol 38:300–305.
57. Herbert J, Goodyer IM, Altham PM et al (1996) Adrenal secretion and major depression in 8–16- year-olds, II. Influence of co-morbidity at presentation. Psychol Med 26:257–263.
58. Herrán A, Sierra-Biddle D, García-Unzueta MT et al (2005) The acute phase response in panic disorder. Int J Neuropsychopharmacol 8:529–535.
59. Hoehn-Saric R, McLeod DR, Lee YB et al (1991) Cortisol levels in generalized anxiety disorder. Psychiatry Res 38:313–315.
60. Hollander E, Liebowitz MR, Gorman JM et al (1989) Cortisol and sodium lactate-induced panic. Arch Gen Psychiatry 46:135–140.
61. Hollander E, Kwon J, Weiller F et al (1998) Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. Psychiatry Res 79:213–217.
62. Hood SD, Hince DA, Robinson H et al (2006) Serotonin regulation of the human stress response. Psychoneuroendocrinol 31:1087–1097.
63. Jezova D, Vigas M, Hlavacova N et al (2010) Attenuated neuroendocrine response to hypoglycemic stress in patients with panic disorder. Neuroendocrinol 92:112–119.
64. Judd FK, Norman TR, Burrows GD et al (1987) The dexamethasone suppression test in panic disorder. Pharmacopsychiatry 20:99–101.
65. Judd FK, Apostolopoulos M, Burrows GD (1994) Serotonergic function in panic disorder: endocrine responses to D-fenfluramine. Prog Neuropsychopharmacol Biol Psychiatry 18:329–337.
66. Kahn RS, Asnis GM, Wetzler S et al (1988) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96:360–364.
67. Kallen VL, Tulen JH, Utens EM et al (2008) Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder. Depress Anxiety 25:131–141.
68. Kathol RG, Noyes R Jr, Lopez AL et al (1988) Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res 24:211–221.
69. Kathol RG, Anton R, Noyes R et al (1989) Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry 25:873-878.
70. Katzman MA, Koszycki D, Bradwejn J (2004) Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Depress Anxiety 20:51–58.
71. Kellner M, Yassouridis A, Jahn H et al (1997) Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology 133:55–61.
72. Kellner M, Knaudt K, Jahn H et al (1998) Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. J Psychiatr Res 32:37–48.
73. Kellner M, Schick M, Yassouridis A et al (2004) Metyrapone tests in patients with panic disorder. Biol Psychiatry 56:898–900.
74. Klein E, Zinder O, Colin V et al (1995) Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Acta Psychiatr Scand 92:399–408.
75. Knopf K, Pössel P (2009) Individual response differences in spider phobia: comparing phobic and non-phobic women of different reactivity levels. Anxiety Stress Coping 22:39–55.
76. Krämer M, Seefeldt WL, Heinrichs N et al (2012) Subjective, autonomic, and endocrine reactivity during social stress in children with social phobia. J Abnorm Child Psychol 40:95–104.
77. Lanzenberger R, Wadsak W, Spindelegger C et al (2010) Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. Int J Neuropsychopharmacol 13:1129–1143.
78. Laufer N, Maayan R, Hermesh H et al (2005) Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia. Psychiatry Res 137:131–136. Erratum in: Psychiatry Res 144:95.
79. Lenze EJ, Mantella RC, Shi P et al (2011) Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry 19:482–490.
80. Lenze EJ, Dixon D, Mantella RC et al (2012) Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder. Int J Geriatr Psychiatry 27:454–462.
81. Lesch KP, Wiesmann M, Hoh A et al (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106:111–117.
82. Levin AP, Doran AR, Liebowitz MR et al (1987) Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 21:23–32.
83. Lieberman JA, Brenner R, Lesser M et al (1983) Dexamethasone suppression tests in patients with panic disorder. Am J Psychiatry 140:917–919.
84. Liebowitz MR, Gorman JM, Fyer AJ et al (1985) Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42:709–719.
85. Lilliecreutz C, Theodorsson E, Sydsjö G et al (2011) Salivary cortisol in pregnant women suffering from blood and injection phobia. Arch Womens Ment Health 14:405–411.
86. Lopez AL, Kathol RG, Noyes R Jr (1990) Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinol 15:23–28.
87. Loosen PT, Chambliss B, DeBold CR et al (1992) Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry 25:192–198.
88. Maddock RJ, Carter CS, Gietzen DW (1991) Elevated serum lactate associated with panic attacks induced by hyperventilation. Psychiatry Res 38:301–311.
89. Martel FL, Hayward C, Lyons DM et al (1999) Salivary cortisol levels in socially phobic adolescent girls. Depress Anxiety 10:25–27.
90. Nesse RM, Cameron OG, Curtis GC et al (1984) Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41:771–776.
91. Nesse RM, Curtis GC, Thyer BA et al (1985) Endocrine and cardiovascular responses during phobic anxiety. Psychosom Med 47:320–332.
92. Pariante CM (2009) Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressants and glucocorticoids. Ann NY Acad Sci 1179:144–152.
93. Peskind ER, Jensen CF, Pascualy M et al (1998) Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol Psychiatry 44:1007–1016.
94. Peterson GA, Ballenger JC, Cox DP et al (1985) The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol 5:100–102.
95. Petrowski K, Herold U, Joraschky P et al (2010) A striking pattern of cortisol non-responsiveness to psychosocial stress in patients with panic disorder with concurrent normal cortisol awakening responses. Psychoneuroendocrinol 35:414–421.
96. Petrowski K, Wintermann GB, Kirschbaum C et al (2012) Dissociation between ACTH and cortisol response in DEX-CRH test in patients with panic disorder. Psychoneuroendocrinol 37:1199–1208.
97. Petrowski K, Wintermann GB, Schaarschmidt M et al (2013) Blunted salivary and plasma cortisol response in patients with panic disorder under psychosocial stress. Int J Psychophysiol doi:pii: S0167–8760(13):00017–2. 10.1016/j.ijpsycho.2013.01.002. (Epub ahead of print)
98. Phillips AC, Batty GD, Gale CR et al (2011) Major depressive disorder, generalised anxiety disorder, and their comorbidity: associations with cortisol in the vietnam experience study. Psychoneuroendocrinol 36:682–690.
99. Pomara N, Willoughby LM, Sidtis JJ et al (2005) Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacol (Berl) 178:1–8.
100. Potts NL, Davidson JR, Krishnan KR et al (1991) Levels of urinary free cortisol in social phobia. J Clin Psychiatry 52(Suppl):41–42.
101. Rapaport MH, Risch SC, Gillin JC et al (1991) The effects of physostigmine infusion on patients with panic disorder. Biol Psychiatry 29:658–664.
102. Roelofs K, van Peer J, Berretty E et al (2009) Hypothalamus-pituitary-adrenal axis hyperresponsiveness is associated with increased social avoidance behavior in social phobia. Biol Psychiatry 65:336–343.
103. Rosnick CB, Rawson KS, Butters MA et al (2013) Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder 17:432–440.
104. Roy-Byrne PP, Uhde TW, Post RM et al (1986) The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143:896–899.
105. Roy-Byrne PP, Cowley DS, Hommer D et al (1991) Neuroendocrine effects of diazepam in panic and generalized anxiety disorders. Biol Psychiatry 30:73–80.
106. Sasaki I, Akiyoshi J, Sakurai R, et al (1996) Carbon dioxide induced panic attack in panic disorder in Japan. Prog Neuropsychopharmacol Biol Psychiatry 20:1145–1157.
107. Seier FE, Kellner M, Yassouridis A et al (1997) Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am J Physiol 272(6.Pt 2):H2630–H2638.
108. Schittecatte M, Garcia-Valentin J, Charles G et al (1995) Efficacy of the clonidine REM suppression test (CREST) to separate patients with major depression from controls; a comparison with three currently proposed biological markers of depression. J Affect Disord 33:151–157.
109. Schruers K, van Diest R, Nicolson N et al (2002) L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology 161:365–369
110. Schweizer EE, Swenson CM, Winokur A et al (1986) The dexamethasone suppression test in generalised anxiety disorder. Br J Psychiatry 149:320–322.
111. Seddon K, Morris K, Bailey J et al (2011) Effects of 7.5% CO2 challenge in generalized anxiety disorder. J Psychopharmacol 25:43–51.
112. Sheehan DV, Claycomb JB, Surman OS et al (1983) Panic attacks and the dexamethasone suppression test. Am J Psychiatry 140:1063–1064.
113. Shlik J, Aluoja A, Vasar V et al (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332–340.
114. Shlik J, Maron E, Tru I et al (2004) Citalopram challenge in social anxiety disorder. Int J Neuropsychopharmacol 7:177–182.
115. Sinha SS, Coplan JD, Pine DS et al (1999) Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res 86:93–98.
116. Siegmund A, Köster L, Meves AM et al (2011) Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia. J Psychiatr Res 45:339–346.
117. Soravia LM, Heinrichs M, Aerni A et al (2006) Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A 103:5585–5590.
118. Staufenbiel SM, Penninx BW, Spijker AT et al (2013) Hair cortisol, stress exposure, and mental health in humans: a systematic review. Psychoneuroendocrinol 38:1220–1235.
119. Stein MB, Uhde TW (1988) Cortisol response to clonidine in panic disorder: comparison with depressed patients and normal controls. Biol Psychiatry 24:322–330.
120. Steudte S, Stalder T, Dettenborn L et al (2011) Decreased hair cortisol concentrations in generalised anxiety disorder. Psychiatry Res 186(2–3):310–314.
121. Stones A, Groome D, Perry D et al (1999) The effect of stress on salivary cortisol in panic disorder patients. J Affect Disord 52(1–3):197–201.
122. Ströhle A, Kellner M, Yassouridis A et al (1998) Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155:610–612.
123. Ströhle A, Holsboer F, Rupprecht R (2000) Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacol 22:251–256.
124. Tafet GE, Idoyaga-Vargas VP, Abulafia DP et al (2001) Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. Cogn Affect Behav Neurosci 1:388–393.
125. Tafet GE, Feder DJ, Abulafia DP et al (2005) Regulation of hypothalamic-pituitary-adrenal activity in response to cognitive therapy in patients with generalized anxiety disorder. Cogn Affect Behav Neurosci 5:37–40.
126. Tancer ME, Mailman RB, Stein MB et al (1994–1995) Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1:216–223.
127. Targum SD, Marshall LE (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28:295–306.
128. Targum SD (1990) Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 28:21–34.
129. Tiller JW, Biddle N, Maguire KP et al (1988) The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 23:261–270.
130. Uhde TW, Joffe RT, Jimerson DC et al (1988) Normal urinary free cortisol and plasma MHPG in panic disorder: clinical and theoretical implications. Biol Psychiatry 23:575–585.
131. Uhde TW, Tancer ME, Gelernter CS et al (1994) Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers. J Affect Disord 30:155–161
132. van der Wee NJ, Fiselier J, van Megen HJ et al (2004) Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls. Eur Neuropsychopharmacol 14:413–417
133. van Duinen MA, Schruers KR, Jaegers E et al (2004) Salivary cortisol in panic: are males more vulnerable? Neuro Endocrinol Lett 25:386–390
134. van Duinen MA, Schruers KR, Maes M et al (2005) CO2 challenge results in hypothalamicpituitary- adrenal activation in healthy volunteers. J Psychopharmacol 19:243–247
135. van Duinen MA, Schruers KR, Maes M et al (2007) CO2 challenge induced HPA axis activation in panic. Int J Neuropsychopharmacol 10:797–804
136. van Duinen MA, Schruers KR, Griez EJ (2010) Desynchrony of fear in phobic exposure. J Psychopharmacol 24:695–699
137. van Megen HJ, Westenberg HG, Den Boer JA et al (1996) The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 6:187–194
138. van Peer JM, Spinhoven P, van Dijk JG et al (2009) Cortisol-induced enhancement of emotional face processing in social phobia depends on symptom severity and motivational context. Biol Psychol 81:123–130.
139. Van Veen JF, Van der Wee NJ, Fiselier J et al (2007) Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. Eur Neuropsychopharmacol 17:637–642
140. van Peer JM, Spinhoven P, Roelofs K (2010) Psychophysiological evidence for cortisol-induced reduction in early bias for implicit social threat in social phobia. Psychoneuroendocrinol 35:21–32
141. van Veen JF, van Vliet IM, Derijk RH et al (2008) Elevated alpha-amylase but not cortisol in generalized social anxiety disorder. Psychoneuroendocrinol 33:1313–1321
142. van Veen JF, van Vliet IM, de Rijk RH et al (2009) Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder. Psychoneuroendocrinol 34:1590–1594
143. van Vliet IM, Slaap BR, Westenberg HG et al (1996) Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 6:103–110
144. van West D, Claes S, Sulon J et al (2008) Hypothalamic-pituitary-adrenal reactivity in prepubertal children with social phobia. J Affect Disord 111:281–290.
145. Villacres EC, Hollifield M, Katon WJ et al (1987) Sympathetic nervous system activity in panic disorder. Psychiatry Res 21:313–321.
146. Vreeburg SA, Zitman FG, van Pelt J et al (2010) Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med 72:340–347.
147. Wedekind D, Bandelow B, Broocks A et al (2000) Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Trans 107:831–837.
148. Wedekind D, Sprute A, Broocks A et al (2008) Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. Curr Pharm Des 14:3518–3524.
149. Westberg P, Modigh K, Lisjö P et al (1991) Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol Psychiatry 30:247–256.
150. Wetzler S, Asnis GM, DeLecuona JM et al (1996) Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 64:77–82.
151. Westenberg HG, den Boer JA (1989) Serotonin function in panic disorder: effect of 1-5-hydroxytryptophan in patients and controls. Psychopharmacology 98:283–285.
152. Whiteford HA, Evans L (1984) Agoraphobia and the dexamethasone suppression test: atypical depression? Aust N Z J Psychiatry 18:374–377.
153. Wiedemann K, Jahn H, Yassouridis A et al (2001) Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 58:371–377.
154. Woods SW, Charney DS, McPherson CA et al (1987) Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 44:365–375